Physician profile
Freda Smith
NPI 1245758762
$14,239.91
in general payments reported to CMS, 2019-2025
21 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,207 · 2022: $2,584 · 2023: $3,668 · 2024: $3,220 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,328 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,328.11 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,428.78 | 2021-2025 | |
| Amgen INC. | $2,176.51 | 2021-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $1,687.16 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,243.03 | 2021-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $1,183.98 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $841.34 | 2021-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $798.34 | 2021-2025 | |
| Genzyme Corporation | $625.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $589.26 | 2022-2025 | Saphnelo |
| Radius Health, INC. | $311.93 | 2021-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $276.19 | 2021-2024 | Orencia |
| Pfizer INC. | $253.74 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $253.25 | 2023-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.33 | 2021-2024 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $100.44 | 2023-2024 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $94.88 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $55.23 | 2022-2024 | Acthar |
| Novo Nordisk INC | $40.20 | 2023 | Wegovy |
| Sandoz INC. | $38.54 | 2023 | Hyrimoz |
| Gilead Sciences, INC. | $15.14 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.